Core Viewpoint - The collaboration between Heptagon Pharmaceuticals and AstraZeneca has deepened with the establishment of an innovative laboratory in Beijing, enhancing the development of next-generation antibody drugs [1] Group 1: Company Developments - Heptagon Pharmaceuticals-B (02142) saw a stock increase of over 6%, reaching HKD 13.23 with a trading volume of HKD 9.94 million [1] - The newly unveiled AstraZeneca Innovation Laboratory in Beijing marks a significant step in the partnership, facilitating a comprehensive R&D process for antibody drugs [1] - The collaboration has evolved into a diversified model that includes R&D cooperation, equity investment, and the establishment of an innovation center in Beijing [1] Group 2: Research and Development - In March, Heptagon Pharmaceuticals and AstraZeneca entered a global strategic partnership to develop next-generation multi-specific antibody therapies targeting immune diseases, tumors, and other conditions [1] - The innovation laboratory is fully prepared and will soon commence operations, integrating Heptagon's antibody drug innovation platform with AI wet and dry lab capabilities [1] - This initiative aims to accelerate the development of therapeutic antibodies across multiple fields [1]